Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19547959 | 0.91 | BACE1 (0.39) | BACE1BACE2AKR1B1 | |
| SCHEMBL10321949 | 0.88 | BACE1 (0.37) | BACE1BACE2AKR1B1P2RX7 | |
| SCHEMBL19547958 | 0.77 | BACE1 (0.34) | BACE1BACE2AKR1B1 | |
| SCHEMBL362554 | 0.77 | BACE1 (0.37) | BACE1BACE2AKR1B1 | |
| SCHEMBL10322811 | 0.76 | BACE1 (0.32) | BACE1BACE2P2RX7 | |
| SCHEMBL10322151 | 0.71 | BACE1 (0.35) | BACE1BACE2 | |
| SCHEMBL10322558 | 0.71 | IRAK4 (0.32) | BACE1BACE2 | |
| SCHEMBL361845 | 0.70 | CHRNA1 (0.34) | BACE1 | |
| SCHEMBL10321829 | 0.67 | BACE1 (0.32) | BACE1BACE2 | |
| SCHEMBL361961 | 0.66 | BACE1 (0.35) | BACE1BACE2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2020-02-13 | — | — | US | disclosed |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20170320864-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2017-11-09 | — | — | US | disclosed |
| US-9550758-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| EP-2663561-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2015-07-23 | — | — | US | disclosed |
| US-8865712-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-8637508-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | disclosed |
| EP-2663561-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
| WO-2012095469-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885BACE2 1/4885AKR1B1 893/4885 |
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 940/4885 |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 1075/4885 |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 940/4885 |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 1075/4885 |
| US-20170320864-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 1075/4885 |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 940/4885 |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 1075/4885 |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885AKR1B1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.